美罗培南联合头孢哌酮舒巴坦对3种多重耐药革兰氏阴性杆菌的抗菌活性研究

发布时间：2018-05-14 05:22

  本文选题：美罗培南 + 头孢哌酮舒巴坦　； 参考：《中国药房》2017年21期

【摘要】：目的:研究美罗培南(MPN)联合头孢哌酮舒巴坦(SCF)对3种多重耐药(MDR)革兰氏阴性杆菌的抗菌活性。方法:收集2016年1-12月泰山医学院附属医院收治患者的痰、血、尿、腹水或引流液标本,从中分离得到的MDR-大肠埃希菌(EC)、MDR-肺炎克雷伯菌(KPN)、MDR-鲍曼不动杆菌(AB)各50株,采用琼脂稀释法、棋盘法测定MPN、SCF、MPN+SCF对MDR-EC、MDRKPN、MDR-AB的半数抑菌浓度(MIC_(50))、90%抑菌浓度(MIC_(90))及平均抑菌浓度(MIC_G),计算联合抑菌浓度(FIC)指数,采用K-B纸片法进行药敏试验。结果:MPN单用时MDR-EC、MDR-KPN、MDR-AB的MIC_G分别为36.82、82.45、34.32μg/mL,SCF单用时MDR-EC、MDR-KPN、MDR-AB的MIC_G分别为42.14、112.67、24.11μg/mL,MPN+SCF时MDR-EC、MDR-KPN、MDR-AB的MIC_G分别为25.97、56.64、11.36μg/mL,MDR-EC、MDR-KPN中的MIC_G为MPN+SCFMPNSCF,MDR-AB中的MIC_G为MPN+SCFSCFMPN,差异均有统计学意义(P0.05)。MPN+SCF对MDR-EC、MDR-KPN、MDR-AB的FIC最高分别为0~0.5(78.00%)、0~0.5(72.00%)、0.5~1.0(82.00%)。结论:MPN联合SCF可有效提高对MDR-EC、MDR-KPN、MDR-AB等MDR革兰氏阴性杆菌的抗菌活性,且两药联用具有协同作用。
[Abstract]:Objective: to study the antibacterial activity of meropenem (MPN) combined with Cefoperazone sulbactam (SCF) against three multidrug resistant (MDR) gram-negative bacilli. Methods: samples of sputum, blood, urine, ascites or drainage fluid were collected from patients admitted to the affiliated Hospital of Taishan Medical College from January to December 2016. Fifty strains of MDR- Escherichia coli were isolated from the patients with MDR- MDR- Klebsiella pneumoniae (KPN)-Acinetobacter baumannii. Agar dilution method and chessboard method were used to determine the 50% inhibitory concentration of MDR-ECRKPNN SCF on MDR-ECRKPNN, MDR-AB) and the average inhibitory concentration of MPN SCF to MDR-ECRKPNN MDR-AB, and to calculate the index of combined inhibitory concentration (FICs). The drug sensitivity test was carried out by K-B disk method. 缁撴灉:MPN鍗曠敤鏃禡DR-EC,MDR-KPN,MDR-AB鐨凪IC_G鍒嗗埆涓，

本文编号：1886536